OMEROS CORP Increase (Decrease) in Inventories
OMEROS CORP (OMER) reported Increase (Decrease) in Inventories of $842.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-12
- OMEROS CORP increase (decrease) in inventories for the quarter ending 2026-06-30 was $659.00K.
- OMEROS CORP increase (decrease) in inventories for the quarter ending 2026-03-31 was $183.00K.
- OMEROS CORP increase (decrease) in inventories for the quarter ending 2025-06-30 was $0.00.
- OMEROS CORP increase (decrease) in inventories for the quarter ending 2025-03-31 was $0.00.
- OMEROS CORP increase (decrease) in inventories for fiscal 2020 was $208.00K, a 80.36% decline from fiscal 2019.
- OMEROS CORP increase (decrease) in inventories for fiscal 2019 was $1.06M.
- OMEROS CORP increase (decrease) in inventories for fiscal 2018 was -$355.00K.
- OMEROS CORP increase (decrease) in inventories for fiscal 2017 was -$685.00K, a 204.42% decline from fiscal 2016.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $659.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $842.00K 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $183.00K 10-Q · filed 2026-05-13 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | |||
| 2021-09-30 | -$266.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$479.00K derived: sum of 2 quarters · filed 2021-11-09 | -$643.00K 10-Q · filed 2021-11-09 | -$830.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-06-30 | -$213.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$377.00K 10-Q · filed 2021-08-09 | -$564.00K derived: sum of 3 quarters · filed 2021-08-09 | -$914.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-03-31 | -$164.00K 10-Q · filed 2021-05-10 | -$351.00K derived: sum of 2 quarters · filed 2021-05-10 | -$701.00K derived: sum of 3 quarters · filed 2021-11-09 | -$20.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-12-31 | -$187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$537.00K derived: sum of 2 quarters · filed 2021-11-09 | $144.00K derived: sum of 3 quarters · filed 2021-11-09 | $208.00K 10-K · filed 2021-03-01 |
| 2020-09-30 | -$350.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $331.00K derived: sum of 2 quarters · filed 2021-11-09 | $395.00K 10-Q · filed 2021-11-09 | $369.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $681.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $745.00K 10-Q · filed 2021-08-09 | $719.00K derived: sum of 3 quarters · filed 2021-08-09 | $705.00K derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $64.00K 10-Q · filed 2021-05-10 | $38.00K derived: sum of 2 quarters · filed 2021-05-10 | $24.00K derived: sum of 3 quarters · filed 2021-05-10 | $475.00K derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | -$26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$40.00K derived: sum of 2 quarters · filed 2021-03-01 | $411.00K derived: sum of 3 quarters · filed 2021-03-01 | $1.06M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $437.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.08M 10-Q · filed 2020-11-09 | $959.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $451.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.10M 10-Q · filed 2020-08-10 | $973.00K derived: sum of 3 quarters · filed 2021-03-01 | $952.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $648.00K 10-Q · filed 2020-05-11 | $522.00K derived: sum of 2 quarters · filed 2021-03-01 | $501.00K derived: sum of 3 quarters · filed 2021-03-01 | $489.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$147.00K derived: sum of 2 quarters · filed 2021-03-01 | -$159.00K derived: sum of 3 quarters · filed 2021-03-01 | -$355.00K 10-K · filed 2021-03-01 |
| 2018-09-30 | -$21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$33.00K derived: sum of 2 quarters · filed 2019-11-12 | -$229.00K 10-Q · filed 2019-11-12 | -$608.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$208.00K 10-Q · filed 2019-08-08 | -$587.00K derived: sum of 3 quarters · filed 2020-03-02 | -$670.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$196.00K 10-Q · filed 2019-05-09 | -$575.00K derived: sum of 2 quarters · filed 2020-03-02 | -$658.00K derived: sum of 3 quarters · filed 2020-03-02 | -$713.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | -$379.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$462.00K derived: sum of 2 quarters · filed 2020-03-02 | -$517.00K derived: sum of 3 quarters · filed 2020-03-02 | -$685.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | -$83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$138.00K derived: sum of 2 quarters · filed 2018-11-08 | -$306.00K 10-Q · filed 2018-11-08 | -$574.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | -$55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$223.00K 10-Q · filed 2018-08-09 | -$491.00K derived: sum of 3 quarters · filed 2019-03-01 | -$875.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | -$168.00K 10-Q · filed 2018-05-10 | -$436.00K derived: sum of 2 quarters · filed 2019-03-01 | -$820.00K derived: sum of 3 quarters · filed 2019-03-01 | -$1.01M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | -$268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$652.00K derived: sum of 2 quarters · filed 2019-03-01 | -$844.00K derived: sum of 3 quarters · filed 2019-03-01 | $656.00K 10-K · filed 2019-03-01 |
| 2016-09-30 | -$384.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$576.00K derived: sum of 2 quarters · filed 2017-11-09 | $924.00K 10-Q · filed 2017-11-09 | $951.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | -$192.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $1.31M 10-Q · filed 2017-08-08 | $1.33M derived: sum of 3 quarters · filed 2018-03-01 | $1.15M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $1.50M 10-Q · filed 2017-05-10 | $1.53M derived: sum of 2 quarters · filed 2018-03-01 | $1.34M derived: sum of 3 quarters · filed 2018-03-01 | $1.40M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$161.00K derived: sum of 2 quarters · filed 2018-03-01 | -$96.00K derived: sum of 3 quarters · filed 2018-03-01 | -$96.00K 10-K · filed 2018-03-01 |
| 2015-09-30 | -$188.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$123.00K derived: sum of 2 quarters · filed 2016-11-09 | -$123.00K 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $65.00K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $568.00K 10-K · filed 2017-03-16 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-15 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |